ecancer

The IMpower-132 trial for non small cell lung cancer

Dr Vassiliki Papadimitrakopoulou - University of Texas MD Anderson Cancer Center, Houston, US

29 Oct 2018

Current clinical landscape for ALK non-small cell lung cancer patients

Dr Riyaz Shah and Dr Maurice Perol

26 Oct 2018

Latest advances in treatment for ALK positive NSCLC

Prof Gordon McVie, Dr Lázaro Quintela

26 Oct 2018

Highlights in early non-metastatic NSCLC and thoracic tumours

Dr Enriqueta Felip - Vall d'Hebron University Hospital (VHIO), Barcelona, Spain

26 Oct 2018

Anti–PD-L1 atezolizumab or chemotherapy as second-line therapy in patients with SCLC

Prof Jean-Louis Pujol - CHRU de Montpellier, Hôpital Arnaud de Villeneuve, Montpellier, France

26 Oct 2018

Highlights in SCLC from ESMO 2018

Dr Noemi Reguart - University of Barcelona, Barcelona, Spain

26 Oct 2018

ABOUND.sqm: nab-paclitaxel and carboplatin induction followed by nab-paclitaxel maintenance in NSCLC

Dr David R. Spigel - Tennessee Oncology, Nashville, USA

26 Oct 2018

ASCEND-8: safety data of ceritinib with or without food in NSCLC

Prof Byoung Chul Cho - Yonsei Cancer Center, Seoul, Republic of Korea

26 Oct 2018

Lung highlights from ESMO 2018

Dr Federico Cappuzzo - AUSL della Romagna-Ravenna, Ravenna, Italy

26 Oct 2018

Erlotinib for neoadjuvant treatment of EGFR NSCLC

Dr Wen-Zhao Zhong - Guangdong General Hospital & Guangdong Academy of Medical Sciences, Guangzhou, China

26 Oct 2018

IMpower132: atezolizumab, carboplatin and pemetrexed as first line treatment in key subgroups with stage IV non-squamous NSCLC

Dr Fabrice Barlesi - Aix-Marseille University, Marseille, France

25 Oct 2018

AURA 3: Mechanisms of osimertinib resistance in patients with EGFR T790M advanced NSCLC

Dr Vassiliki A. Papadimitrakopoulou - University of Texas MD Anderson Cancer Center, Houston, USA

25 Oct 2018

More from ecancer